Medicare AdvantageCoverageMedium impact
MA08.101c, Canakinumab (Ilaris®)
Independence Blue Cross·Rheumatology, Oncology, Hematology +1 more·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.101c for Canakinumab (Ilaris®) has been reissued and will become effective May 28, 2025. This is a pharmacy policy update that may affect coverage criteria, prior authorization requirements, or billing procedures for this specialized inflammatory condition medication.
Action Required
Before May 28, 2025: Billing team should review the complete policy details at the source URL to understand specific changes to Canakinumab (Ilaris®) coverage requirements for Medicare Advantage patients. Update any prior authorization workflows or billing procedures as specified in the full policy document.